ÀüÀ̼º ¾ç¼º ERBB2 À¯¹æ¾ÏÀÇ Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel Ä¡·áÈ¿°ú ºñ±³
ÀÓ»óÁú¹®
|
ÀüÀÌµÈ ERBB2 À¯¹æ¾Ï Ä¡·á¿¡¼ Neratinib Plus Paclitaxel Åõ¿©´Â Trastuzumab Plus Paclitaxel¿¡ ºñÇØ »ýÁ¸À²¿¡ Â÷ÀÌ°¡ Àִ°¡?
|
±Ù°Å±â¹Ý ´äº¯
|
ÀÌÀü¿¡ Ä¡·áµÇÁö ¾Ê¾Ò´ø ÀüÀ̼º ¾ç¼º ERBB2 À¯¹æ¾ÏÀÇ Neratinib-Paclitaxel Åõ¿©´Â Trastuzumab-Paclitaxel Åõ¿©¿Í ºñ±³ÇÏ¿© progression-free survival Ãø¸é¿¡¼ Â÷ÀÌ°¡ ¾ø¾ú´Ù.
|
¼ÁöÁ¤º¸
|
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial LID - 101001/jamaoncol20160237 (2016). JAMA Oncology Apr ; 90( 9 ): DOI: 10.1001/jamaoncol.2016.0237.
|
Áúº´Æ¯¼º
|
Àç¹ßµÇ°Å³ª ÀüÀÌµÈ ¾ç¼º ERBB2-Positive À¯¹æ¾Ï
|
¿¬±¸¼³°è
|
Randomized Clinical Trial: 2009³âºÎÅÍ 2014³â±îÁö 34°³±¹ÀÇl 188¼¾ÅÍ
|
¿¬±¸´ë»ó
|
18¼¼ ÀÌ»óÀÇ ÁßÃ߽Űæ°è ÀüÀÌ¿¡ ¹«Áõ»óÀ» ³ªÅ¸³½ 479¸íÀÇ À¯¹æ¾Ï ȯÀÚ
|
½ÃÇ豺
|
Neratinib-paclitaxel [n = 242]; Neratinib (240 mg/d orally) combined with paclitaxel (80 mg/m2 on days 1, 8, and 15 every 28 days)
|
´ëÁ¶±º
|
Trastuzumab-paclitaxel [n = 237]; Trastuzumab (4 mg/kg then 2 mg/kg weekly) combined with paclitaxel (80 mg/m2 on days 1, 8, and 15 every 28 days)
|
Æò°¡ÁöÇ¥
|
Progression-free survival
|
ÁÖ¿ä°á°ú
|
Neratinib-paclitaxelÀÇ °æ¿ì ÁßÃß ½Å°æ°è Àç¹ßÀÇ ºóµµ°¡ ³·¾ÒÀ¸³ª (HR, 0.45, 95 % CI, 0.29-0.79, P = .002) 0.26-0.78; P = .004), Median progression-free survival¿¡¼´Â µÎ±º°£¿¡ 12.9 °³¿ù·Î ³ªÅ¸³ª Â÷ÀÌ°¡ ¾ø¾ú´Ù(Neratinib-paclitaxel and 12.9 months (95% CI, 11.1-14.8) with trastuzumab-paclitaxel (hazard ratio [HR], 1.02; 95% CI, 0.81-1.27; P =.89).
|
±Ù°Å¼öÁØ
|
High
|
ÀÛ¼ºÀÚ
|
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC)
Copyright © 2015 Medical Research Information Center (MedRIC) Editors
|